Liquid Biopsy in Solid Malignancy

Matthew Scarlotta, Cem Simsek, Amy Kim

Research output: Contribution to journalArticle

Abstract

The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.

Original languageEnglish (US)
Pages (from-to)284-296
Number of pages13
JournalGenetic Testing and Molecular Biomarkers
Volume23
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Biopsy
Neoplasms
Circulating Neoplastic Cells
Urine
DNA
Research
Therapeutics

Keywords

  • cancer
  • circulating DNA
  • circulating tumor cells
  • extracellular vesicles
  • liquid biopsy

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Liquid Biopsy in Solid Malignancy. / Scarlotta, Matthew; Simsek, Cem; Kim, Amy.

In: Genetic Testing and Molecular Biomarkers, Vol. 23, No. 4, 01.04.2019, p. 284-296.

Research output: Contribution to journalArticle

Scarlotta, Matthew ; Simsek, Cem ; Kim, Amy. / Liquid Biopsy in Solid Malignancy. In: Genetic Testing and Molecular Biomarkers. 2019 ; Vol. 23, No. 4. pp. 284-296.
@article{2426a90f1872474ca6304530ab4ec000,
title = "Liquid Biopsy in Solid Malignancy",
abstract = "The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. {"}Liquid biopsy{"} refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional {"}solid biopsy{"}. In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.",
keywords = "cancer, circulating DNA, circulating tumor cells, extracellular vesicles, liquid biopsy",
author = "Matthew Scarlotta and Cem Simsek and Amy Kim",
year = "2019",
month = "4",
day = "1",
doi = "10.1089/gtmb.2018.0237",
language = "English (US)",
volume = "23",
pages = "284--296",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Liquid Biopsy in Solid Malignancy

AU - Scarlotta, Matthew

AU - Simsek, Cem

AU - Kim, Amy

PY - 2019/4/1

Y1 - 2019/4/1

N2 - The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.

AB - The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.

KW - cancer

KW - circulating DNA

KW - circulating tumor cells

KW - extracellular vesicles

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85064456228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064456228&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2018.0237

DO - 10.1089/gtmb.2018.0237

M3 - Article

C2 - 30916594

AN - SCOPUS:85064456228

VL - 23

SP - 284

EP - 296

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 4

ER -